Study:
Prospective, Randomized, Multicenter Trial of Aerosolized Albuterol Versus Placebo in Acute Lung Injury
Rationale:
n/a
Purpose:
Acute Respiratory Distress Syndrome (ARDS) and a lesser condition that occurs prior to ARDS,
Acute Lung Injury (ALI), are medical conditions that occur when there is severe inflammation
and increased fluids (edema) in both lungs, making it hard for the lungs to function
properly. Patients with these conditions require treatment that includes the use of a
breathing machine (ventilator). The purpose of this study is to find out whether giving
albuterol (a drug commonly used in asthmatics) or not giving albuterol to patients with ALI
or ARDS makes a difference in how long it takes for a patient to be able to breath without
the ventilator.
Study Status: Terminated
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Respiratory Distress Syndrome, Adult |
Drug: Albuterol Sulfate USP
Procedure: Mini-Bronchoalveolar Lavage
Drug: Placebo |
Phase 2/Phase 3 |
Verified by
National Heart, Lung, and Blood Institute (NHLBI)
February, 2012
Sponsored by: National Heart, Lung, and Blood Institute (NHLBI)
Information provided by: National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov identifier: NCT00434993
Study Type: Interventional
Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Cleveland Clinic Foundation
Cleveland, Ohio
United States
Michael A. Matthay, MD., Principal Investigator
Roy Brower, MD., Study Chair